Brief: Mirati Therapeutics Reports First Quarter 2023 Financial Results And Recent Corporate Updates
09/05/2023 21:31
May 9 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND RECENT CORPORATE UPDATES
* Q1 EARNINGS PER SHARE VIEW $-3.55, REVENUE VIEW $4.8
MILLION --
REFINITIV IBES DATA
* NET REDUCTION IN CASH, CASH EQUIVALENTS AND SHORT-TERM
INVESTMENTS FOR Q1 WAS $181.5 MILLION
* EXPECTS 2023 NET CASH BURN TO ANNUALIZE WITHIN A RANGE OF
$525
MILLION TO $580 MILLION
Source text for Eikon: ID:nPn4jC5Bga
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)